Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Adverum Biotechnologies Stock Quote

Adverum Biotechnologies (NASDAQ: ADVM)

Price as of April 18, 2024, 4:00 p.m. ET

Adverum Biotechnologies Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
ADVM +21.20% -81.35% -28.51% -95%
S&P +20.88% +72.88% +11.56% +160%

Adverum Biotechnologies Company Info

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

News & Analysis


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.